Members of an FDA panel assessing whether to approve Sanofi’s new drug, Zynquista, could not agree. On January 17, 2019, the panel was evenly split, 8-8, on whether the drug’s benefits outweighed its risks. The drug will receive its verdict from the FDA by March 22. If it’s approved, Zynquista,
a dual inhibitor targeting both SGLT1 and SGLT2, would be the first oral diabetes drug approved as an add-on to insulin to improve blood sugar control in patients with Type 1 diabetes. Read more